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IDENTIFICATION OF MORE POTENT AND EFFICACIOUS ANALOGS
OF THE NOVEL HOST-DERIVED IMMUNOSTIMULANT EP67
Abdulrahman Mohammed Alshammari, Ph.D.
University of Nebraska Medical Center, 2019
Supervisor: Joseph A. Vetro, Ph.D.
EP67 is a decapeptide agonist of C5a Receptor 1 (C5aR1/CD88) based on
the C-terminus of human C5a that selectively activates mononuclear phagocytes
over neutrophils to stimulate protective innate and adaptive immune responses
while potentially minimizing neutrophil-mediated toxicity. Pro7 and N-methyl-Leu8
(nme-Leu8) induce structural changes within EP67 that increase potency and
selective activation vs. neutrophils. Cis/trans isomerization at Pro7, however, likely
limits the activity of EP67 and the low coupling efficiency between Pro7 and nmeLeu8 increases scale-up costs for clinical use. Thus, the goals of this project were
to (i.) develop a clinically relevant, high-throughput assay for screening
immunostimulant activity in primary human mononuclear phagocytes (monocytes,
unpolarized (M0)-monocyte-derived macrophages, monocyte-derived dendritic
cells) and neutrophils and (ii.) determine whether replacing Pro 7 with
cyclohexylalanine and/or nme-Leu8 with leucine adversely affects EP67 potency
and efficacy in human mononuclear phagocytes and selective activation vs. human
neutrophils. We found that, depending on the mononuclear phagocyte and
cytokine, EP67 analogs (i.) had similar or lower EC 50 and similar, increased, or
decreased EMAX for IL-6 and TNF-α secretion from mononuclear phagocytes 24 h
after treatment and (ii.) EP67 analogs does not affect selective activation of

9

mononuclear phagocytes vs. neutrophils. Thus, replacing Pro 7 and/or nme-Leu8
with amino acids that induce similar structural changes affects the activity of EP67
depending on the mononuclear phagocyte and cytokine but is an amenable
approach for future analogs.
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1
1.1

GENERAL INTRODUCTION
Chance and necessity: The first attempt of immunostimulants
The concept of immunostimulants was initiated early last century when Dr.

William Coley, a renowned surgeon at New York Memorial hospital, utilized killed
streptococcus pyogenes and Serratia marcescens (Coley’s vaccine) to treat
lymphomas, melanomas, and myelomas. His insight was that active defense
against microbes reinforced the body's fight against cancer. This observation leads
to the origin of the combination of streptococcus pyogenes and Serratia [1].
Initially, Coley and other researchers were using live bacteria; however, the fatal
infection caused by these induced bacteria led to the use of inactivated organisms.
After the success of using inactivated organisms, several other microbial
substances were clinically approved to be used in the treatments of infections and
cancers (Table 1.1) [2]. However, the use of immunostimulants to enhance the
humoral immunity was recognized later, in 1925, when Gaston Ramon observed
that giving diphtheria toxoid with the combination of starch, fish oils, and several
plants extract can enhance the response of antibodies towards the toxoid in the
horses. Following this, after a year, Glenny also observed the same effect with
Alum, which was approved later as an adjuvant in a variety of vaccines [3-5].
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Immunostimulants are either natural or synthetic substances that are used
to induce and stimulate nonspecific activation of the immune system, unless they
are associated with antigens (e.g., adjuvants in vaccines). Immunostimulants can
amplify different effectors of the immune response, including phagocytosis,
complement system, protective secretory antibodies, α- and γ-interferon release,
T- and B-lymphocytes, and synthesis of pulmonary surfactant [1,6]. They also
support the release of endogenous immune mediators such as cytokines and
chemokines that aids in the treatments of several chronic diseases such as
infectious diseases, immunodeficiencies, or cancer. Immunostimulants vary based
on their origin, mechanism of action, and application (preventive, therapeutic, or
adjuvants) [1].

1.2

The impact of immunostimulants
Through the last three decades, there have been intensive researches that

are carried out on the development, preparation, experimental, and clinical
characteristics of immunostimulants. From the therapeutic point of view, the ability
of immunostimulants to stimulate the immune system has a great potential as
adjuvant therapy in cancer, chronic infections, immunodeficiency diseases, and
vaccines [6,7].
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One of the greatest achievements of modern medicine has been the
development of antimicrobials for the treatment of infectious diseases [8]. Antibiotic
resistance, however, has turned into a significant medical problem. For instance,
staphylococcus aureus penicillin resistance has been reported since 1947, four
years after the start of large-scale production, and since then, the amount and
variety of pathogenic strains resistant to new classes of antibiotics have increased
[9,10]. This has made various treatment schemes with antimicrobial drugs less
effective. Therefore, the interest in the development of new alternatives for the
treatment of bacterial infections has become a global emergency [11]. Combating
pathogenic organisms by combined therapies involving appropriate immune
response molecules and antimicrobial drugs represents an apparent and
successful therapeutic paradigm for the treatment of acute and chronic infectious
diseases [12]. Several studies have demonstrated the abilities of different
immunostimulants to stimulate host defense mechanisms for the prophylaxis and
treatment of diverse viral, bacterial, parasitic, and fungal diseases. The potential
of these agents to stimulate the immune response can be used for treatment or as
adjuvant therapy of various microbial infections [13].

In the case of vaccination, adjuvants are substances used to increase the
cellular/humoral response to a used immunogen to prevent infectious diseases. In
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general, among the mechanisms that adjuvants use to boost the immune response
are the "deposit" effect, antigen presentation, antigen distribution, immune
modulation/activation, and induction of cytotoxic lymphocytes [14,15]. Adjuvants
can significantly improve the protective immune response, and today their in-depth
knowledge is the key to the development of better vaccines. The classic adjuvant
at present is the aluminum salts (aluminum phosphate and aluminum hydroxide),
which discovered in the first half of the twentieth century [16]. These adjuvants, in
addition to being deposited in a particulate manner in the tissues and inducing
phagocytosis of the antigen, activate macrophages, stimulate the T helper 2
response (Th2) and are frequently used when the immunological effector sought
is antibodies, since they stimulate the production of IgG 1 [16,17]. They do not
significantly stimulate cellular immunity, since the adjuvant adsorbs to proteins,
and the physicochemical conditions of antigen and adjuvant must be considered
in this process. Recently, new aspects of the mechanism of action of aluminum
hydroxide have been described, including the activation of the innate immune
system and the production of IL-1, through the activation of the NPLR3 protein
complex in monocytes and induction of immunogenic dendritic cells [18]. AS04 is
another approved adjuvant that is made by a combination of aluminum salt and a
Toll-like receptor 4 agonist (TLR4), monophosphoryl lipid A (MPL). MPL is
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produced by detoxification and purification of lipopolysaccharides (LPS),
originating a non-toxic molecule with immunostimulatory properties of TLR. The
AS04 system causes a local transient response of cytokines that increases the
activation of monocytes, dendritic cells, and antigen-specific T cells. This adjuvant
system has been incorporated into some vaccines, such as Cervarix, approved for
use against human papillomavirus and in the hepatitis B surface antigen vaccine
(Fendrix), developed for patients with kidney disease and high risk of hepatitis B
[19,20].

Also, natural, synthetic, or modified adjuvants are evaluated, which can be
used to stimulate the immune response against specific pathogens. Such is the
case of adjuvants MF59, an emulsion of squalene-tween 80 and sorbitan trioleate,
which is a natural organic compound originally extracted from the shark's liver.
MF59 is approved in Europe and is present in various vaccines, such as influenza.
Another example is AS03, oil-water emulsion, and vitamin E and AS02 containing
MPL and QS21 oil-water emulsion [21,22].
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1.3

A turning point: Better understanding of immunology and its impact on
the development of immunostimulants
For decades, the discovery and development of novel immunostimulants

have been based on observations and experiments, without explicit immunological
knowledge of the mechanism that causes the immunostimulatory effect. However,
the discovery of the innate immune system's ability to recognize molecular
pathogen-associated molecular patterns (PAMPs), via specialized receptors,
pattern recognition receptors (PRRs), has had significant consequences for the
development of new immunostimulants. PRRs are innate immunity receptors
being involved in many immunological and immunopathological processes.
Recently, several new families of PRRs have been identified including Toll-like
receptors (TLRs), C-type lectin-like receptors (CLRs), nucleotide oligomerization
domain (NOD) like receptors (NLRs), and Retinoic acid-inducible gene-1 (RIG-1)
like receptors (RLRs) [23-25].

The innate immune system acts as a sentinel: the cells that are activated
on contact with the PAMPs (especially the dendritic cells), which triggers their
maturation, which enables them to efficiently present the antigen to the T
lymphocytes, in the context of major histocompatibility complex (MHC system)
[26]. The recognition of PAMPs by PRRs (especially TLRs) generates a cascade
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of activation within the immune cells. This cascade results in the activation of a
nuclear transcription factor (NFκB), which allows the transcription of inflammatory
mediator genes such as proinflammatory cytokines (IL-1,IL-6, and TNFα),
chemokines, adhesion molecules and cyclooxygenases-2; leading to attract more
T cells to the point of inflammation and cause them to differentiate into polarized
effectors. This discovery naturally led to the use of PAMPs as immunostimulants
[27].

1.4

Classification of immunostimulants
Most immunostimulants reviews during recent decades followed different

criteria to classify the immunostimulants. In this section, immunostimulants are
classified based on their origin. Also, the mechanism of actions of these
substances will be highlighted according to the cell induction capacity and the type
of response they initiate.

1.4.1 Microbially-derived immunostimulants
1.4.1.1 Bacterial lipopolysaccharides endotoxins
The lipopolysaccharides of Gram-negative bacteria are prototype of
PAMPs. LPS contains a fraction called lipid A, composed of fatty acids linked by
steric bonding to N-acetylglucosamine molecules. Another fraction is the R region,
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which is composed of hexoses, and the third fraction is the so-called O antigen,
which is specific for each bacterial species [28]. These molecules are essential to
the bacterial wall structure and are well-known activators of the inflammatory
response. The PRRs involved in the recognition of LPS has long remained
unknown, however, Poltorak and colleagues have identified the role of TLR4 as
LPS-sensing receptor. The recognition of LPS via TLR4 induce a signaling
pathway involving the myeloid differentiation 88 (MyD88) cytoplasmic molecule
that contains a Toll-Interleukin receptor domain (TIR domain) and a death domain
(DD). After recruitment, the MyD88 molecule induces the recruitment and the
activation of the Interleukin-1 receptor-associated kinase 1 and 4 (IRAK kinases 1
and 4), responsible for the activation of the molecule TNF Receptor Associated
Factor 6 (TRAF6). This then activates the NFκB, which is involved in the induction
of many genes, mainly pro-inflammatory cytokines. Moreover, activation of TLR4
induce the activation of the TRIF molecule, a step required to produce type I
interferon: TRIF activates the IRF3 transcription factor, and it is binding on the
promoter of the IFNβ gene [29-31]. Several synthetic analogs of the constituents
of biologically active bacterial cell walls, such as lipid A, part of the LPS of gramnegative bacteria, and synthetic muramyl dipeptide derived from bacterial
peptidoglycan have prepared [32,33].
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1.4.1.2 Unmethylated Cytosine-Phosphate-Guanosine Motifs (CpG Motifs)
The synthetic oligonucleotides (ODN) of the CpG are single-stranded DNA
sequences containing CG or CpG motifs. There are several classes of CpG-like
ODNs (A, B, C, and P) that differ in their structure and immunostimulatory effect
[34]. The CpG type ODNs are potent immunostimulants capable of activating most
innate immunity cells such as natural killer cells (NK cells), T lymphocytes, B cells,
monocytes, macrophages and DCs by detecting the intracellular presence of the
cell DNA of phagocytotic pathogens [34,35]. The CpG type ODNs are
predominantly recognized via the TLR9 receptor, which is located in endosomes
and is primarily expressed by plasmacytoid Dendritic Cell (pDC) and B cell
lymphocytes in humans, and in addition by the myeloid lineage (macrophages,
monocytes, myeloid dendritic cells) in mice [36]. Human TLR9 would also be
expressed in monocytes and macrophages but at a lower level [37].

Intracellular activation after TLR9 binding leads to the activation of mitogen
activated protein kinases (MAP kinases) and NFκB pathways [36]. The attachment
of CpG-like ODD to TLR9 in B cells triggers the secretion of cytokines such as IL6 and IL-10, cell proliferation, and expression of MHC class II molecules [38]. Type
A ODDs strongly activate NK cells and pDCs and cause strong interferon- γ (IFNγ) secretion by pDCs while type B ODNs strongly activate B-cells and pDCs. The
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C-type ODNs combine the properties of the two previous types. P-type ODNs
stimulate B-cells, activate pDCs and induce strong IFN-γ secretion by pDCs such
as type-A ODNs [36].

CpG-type ODNs are used either alone to promote an immune response, or
in combination

with

other treatments

such

as monoclonal

antibodies,

chemotherapy, radiotherapy to increase its effectiveness, or as adjuvants in a
vaccine. Several studies on solid tumor models have shown the effect on tumor
development of the CpG-type ODN used alone [39-41]. For instance, a murine
model of neuroblastoma has shown that a daily injected of CpG-type ODN near
the tumor led to tumor regression in half of the animals, and the appearance of a
prolonged protective immune response. Moreover, the combination of therapeutic
monoclonal antibodies with CpG-type ODN increases the cytotoxicity relayed by
antibodies by stimulating macrophages and NK cells. The combination of
Trastuzumab (anti-Her2neu antibody) with CpG-type ODN, for instance, has
shown to inhibit murine tumor growth in 96% of the human cell lines (MCF-7 and
BT474 xenografts) [42]. In an orthotopic model of a pancreatic tumor, the
combination of Gemcitabine and ODN CpG type allows to delay tumor
development and increase the survival rate and reduces the spread of the tumor
in the peritoneal cavity than the chemotherapeutic treatment alone [43]. Many
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other mouse model studies have also shown improved efficacy of therapeutic
treatments when combined with CpG-like ODNs. As a result, several clinical trials
using CpG-type ODDs alone or in combination are underway [44].

1.4.1.3 Bacillus Calmette and Guerin (BCG) and active components of the
mycobacterial cell wall
BCG is a highly complex immunogen that induces a cellular-type immune
response [1,45]. In 1921 Calmette and Guerin, after 13 years and 230 cultivation
passes of a strain of Mycobacterium bovis, obtained a non-pathogenic but
immunogenic bacillus, whose use managed, with varying efficacy, to reduce the
incidence of tuberculosis and tuberculous meningitis for its systemic protective
immunostimulatory effect [1].

Although BCG has been used successfully for many years, details of its
antineoplastic mechanism of action remain unknown. It is thought that a wide
variety of immunocompetent cells, as well as uroepithelial cells and even the same
bladder neoplastic cells, participate in the immune mechanism that occurs during
intravesical therapy with BCG [45]. The anti-tumor effects of BCG appear to be
related to immunological mechanisms, which are reflected by a transient increase
in several cytokines and the presence of immunocompetent leukocytes activated
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in the urine within 24 hours after instillation [46]. Some studies have revealed that
CD4 + T cells and monocytes act as accessory cells in cell-mediated cytotoxicity
induced by BCG [47]. Certainly, another large number of molecules and cells must
participate in BCG-induced immune stimulation, such as the family of adhesion
molecules, heat shock proteins, toll-like receptors, nitric oxide, dendritic cells and
their subpopulations, the regulatory T cells and the recently described Th17 cells
[48,49].
1.4.1.4 β-glucans
β-glucans are polysaccharides formed from units of glucose linked together
in β-1,4 and β-1,6. They differ in their structures (length and ramifications). These
are compounds of the walls of fungi, yeasts, bacteria, algae, and plants, known in
traditional medicine as immunostimulants [50,51]. Indeed, fungi and algae have
branches rather than 1 to 6, while bacteria and plants have more side chains in 1
to 4. The existing multiple β-glucans exhibit differences in immunostimulatory
properties, and their polydispersity explains the complexity of purifying and
studying them [52].
Macrophages can internalize β-glucans, fragment them in endosomes, and
the released fragments of soluble β-glucans are then recognized by different
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immune cells with specific receptors [53]. The primary receptors of known βglucans are lectins such as dectin-1 expressed on the surface of macrophages,
neutrophils, and dendritic cells and integrins such as the type 3 complement
receptor (CR3) expressed on the surface of NK cells and neutrophils [54,55]. They
can also be recognized by the scavenger receptor and by the LactosylCeramide
receptor (LacCer) expressed on the surface of neutrophils. CR3 recognizes
opsonized or non-complemented β-glucans and directly induces phagocytosis.
Thus, by binding to this receptor, β-glucans would cause a CR3 conformational
change allowing better exposure of the iC3b binding domain, thus facilitating the
interaction between integrin and its ligands and thus the activation of NK cells and
neutrophils involved in the elimination of cancer cells [56].

Several clinical trials have demonstrated that the combination of
chemotherapy with β-glucans promotes the activation of CR3 on NK cells and
increases the effectiveness of treatment [57]. A study has shown that a group of
mice inoculated with tumor cells had a significant slowing down of the increase in
tumor size with a treatment combining the antitumor monoclonal antibody and the
β-glucans compared to treatment with the antibody alone or β-glucans alone. Also,
100 days after tumor implantation, a significant percentage of survival of mice
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treated with monoclonal antibodies and β-glucans was observed, compared to
other types of treatments [58].

1.4.2 Synthetic-derived immunostimulants
1.4.2.1 Levamisole (Ergamisol):
Levamisole was initially developed as an anthelmintic and widely used for
the treatment of gastrointestinal and tissue helminths [59]. Various studies have
been carried out to demonstrate the immunostimulatory activity of levamisole,
some of them with conflicting results. This drug, when administered in combination
with the canine parvovirus vaccine, boosted antibody production, increased
phagocytic activity and stimulated lymphocyte proliferation activity and similarly
potentiated the protective antibody response to hepatitis B vaccination in patients
with hemodialysis [60]. The effect of levamisole on cellular immunity is mainly on
anaerobic T lymphocytes, macrophages and polymorphonuclear leukocytes [61].
In 2000, the US FDA was withdrawn Levamisole from the market due to its ability
to cause serious adverse effects, including agranulocytosis [62]. Interestingly,
levamisole has been found as an adulterant in cocaine and can lead to a variety
of adverse effects in individuals using this drug [63].
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1.4.2.2 Isoprinosine
Isoprinosine is an antiviral, antitumor, and immunostimulatory agent with
superior properties to levamisole. Isoprinosine works as a thymomimetic hormone,
promoting the production of a factor that activates the functions of the various
cytokines and increases the production of IL-1, IL-2, and interferon. It facilitates
the differentiation of T lymphocytes and the increase of its receptors [64]. It is also
able to increase the phagocytosis function of macrophages and cellular and
humoral responses [65]. It is used in the treatment of viral infections, such as
herpes simplex and encephalitis of viral origin [66].

1.4.3 Thymus-derived immunostimulants
Thymic hormones are soluble substances obtained from the thymus
(Thymopoietin, Thymostimulin, Thymosin, Thymulin), which were attributed with a
favorable effect of maturation of T lymphocytes in this organ. This hormone is
considered to induce maturation of pre-T cells; therefore, the purified hormone has
therapeutic application potentials in various states of T-cell deficiency [67]. A
recombinant peptide derived from this hormone; thymosin alpha-1 induces
increases in the production of IL-2 and the expression of IL-2 receptors in T
lymphocytes. This peptide is being studied in clinical experiments for the treatment
of cancer and chronic active hepatitis [68]. In general, thymic hormones may have
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utility in primary and secondary immunodeficiencies causing differentiation of nonfunctional precursors in immunocompetent T cells. Among the side effects
observed with these factors are allergic reactions, especially with poorly purified
preparations [69].

1.4.4 Host-derived immunostimulants
1.4.4.1 Exogenous Cytokines
Cytokines are specific non-antigen soluble proteins, mostly produced by
leukocytes that regulate immune system cells and inflammatory processes [2].
These regulatory molecules are involved in the protective response against
neoplasms and infections [2]. Although some cytokines are produced by
mononuclear cells, either constitutively or in response to activation signals, their
induction has been shown to be diminished in patients with chronic infectious
diseases so they could benefit from the exogenous administration of these
molecules [70]. When cytokines are used to induce immune response, the local
advantages are 1) generate high concentrations of cytokines locally, similar to the
body's response against foreign antigens; 2) take advantage of the paracrine
effects of cytokines in a sustained way that activates the immune system [70,71].
Some cytokines stimulate the production of others, therefore that they interact,
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either synergistically or antagonistically and thus their local and systemic effects
are intimately involved in the control of host infections [70].

Advances in the understanding of the role of cytokines in inflammatory and
immune disorders have led to the development of cytokine-based therapies. These
molecules, their receptors and their signaling pathways, are promising candidates
for therapeutic participation [71]. The precise understanding of the critical balance
between pro-inflammatory and regulatory cytokines in microbial infections is
essential to be able to use and regulate with certainty and safety the beneficial
effects that are sought through cytokine therapy, thus exploiting its great potential
to increase resistance against various pathogens [72]. T helper cells 1 (Th1) are
crucial for orchestrating cytokine responses and of utmost importance for the
elimination of infectious diseases. These cells produce IFN-γ, TNF-β, and IL-2
required for the effective development of the cell-mediated immune response
against intracellular microorganisms [73]. On the other hand, Th2 produce IL-4 and
IL-5 that enhance humoral immunity to T cell-dependent antigens and immunity
against helminth infections [73]. Therefore, patients in whom cytokine production
is altered or in those who carry out chemotherapy treatments, which causes an
increased susceptibility to infections, may benefit from exogenous cytokine
therapy [74].
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Interferons are cytokines initially described in 1957 with an action that
interfered with viral replication. They were initially classified according to the cell
that secreted them into IFN-α or leukocyte (produced by mononuclear
phagocytes), IFN-β, or fibroblastic (produced by fibroblast) and IFN-γ (produced
by lymphocytes and NK cells). They are currently classified according to their
receptors and the homology of their sequences. Interferons such as IFN-α and
INF-β are classified as type I, and IFN-γ is the only one classified as type II [75].
The mechanism of action of IFN-α and INF-β is related to inhibition of
replication and viral spread. It also activates and regulates the expression of the
MHC I. IFN-γ stimulates and activates macrophages, neutrophils and NK cells in
their phagocytic and cytotoxic functions, in addition to inciting the expression of
molecules of the MHC I [75]. IFN-α (INTRON A) is indicated in the treatment of
hepatitis B and C and as an adjuvant in myeloma [76]. On the other hand, IFN-γ
(ACTIMMUNE) is recommended as adjuvant therapy in chronic granulomatous
disease, a primary immunodeficiency defect in phagocytic function in neutrophils
and malignant osteopetrosis [77].

Interleukin 2 is a potent activator of T lymphocytes, activates NK cells,
macrophages, B lymphocytes and stimulates the release of several cytokines. Its
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antitumor effect is mediated by promoting the activation of NK cells, lymphokineactivated killer cells (LAK) and other cytotoxic cells, as well as the induction of IFNγ, TNF-α [78]. The use of IL-2 in therapy cancer gene has been widely used in
various preclinical tumor models, including hepatocellular carcinoma, head, neck
carcinoma, sarcomas, plasmacytoma, breast carcinoma, lymphomas, and in
cervical cancer [79]. Particularly, the effect IL-2 adjuvant in cervical cancer has
been tested in tumor models associated with human papillomavirus (HPV). It has
been shown that treatment with the recombinant protein of IL-2 gene, administered
intratumorally, significantly reduces the progression of HPV-associated tumors
and inhibits the formation of recurrent tumors after being removed by surgery [80].

Cytokines have also been described as a double-edged sword, as they
have been attributed to both beneficial and harmful effects. Capillary filtration
syndrome is the main dose-dependent toxicity in cytokine therapy, specifically IL2. This syndrome is characterized by an increase in vascular permeability
accompanied by extravasation of fluids and proteins that produces interstitial
edema and organ failure. The pathogenesis of endothelial cell damage is
complicated. It may involve the activation or damage of endothelial cells and
leukocytes, the release of cytokines and mediators of inflammation, the alteration
of cell-cell, matrix-cell adhesion, and function of the cytoskeleton [81,82]. The
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efficacy of exogenous cytokines capable of enhancing normal host defense
mechanisms may be reduced to immunocompromised patients lacking effector
cells or containing disease-related factors that prevent lymphocyte activation.

1.4.4.2 Heat shock proteins
Heat shock proteins (Hsps) are proteins that are synthesized by the body in
response to stress (temperature, exposure to heavy metals, infections, etc.). They
have been grouped into families according to their molecular mass: Hsps 60, Hsps
70, Hsps 90, Hsps 110. These proteins are part of the family of molecular
chaperones, and they associate with peptides or proteins that are not correctly
folded. Hsps are used to prevent the accumulation of incorrectly folded proteins.
Indeed, heat stress can result in denaturing proteins [83].

The participation of Hsps in infections and immune reactions occurs at
many levels. It is therefore not surprising to observe a growing interest in these
proteins in the search for new vaccines. For instance, mice vaccinated with a cell
line that expresses a mycobacterial Hsps 60 show remarkable protection against
lethal doses of Mycobacterium tuberculosis [84]. Moreover, Hsps 70 and Hsps 25
are expressed during the cycle of the acquired immunodeficiency virus (HIV-1) and
associate with specific viral proteins. They then serve as a target for NK cells and
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the antibody-dependent cytotoxic cellular response; they have therefore been
proposed as a "vehicle" (or vector or excipient) for the antigen in the development
of HIV-1 vaccines [85]. In the case of autoimmune diseases, it has also been
observed that the administration of epitopes of Hsps 60 and Hsps 70 could
modulate the autoimmune reaction via immunization involving suppressor T cells
or via induction of lymphocyte clone anergy. Self-reactive T involved; this can be
used as a preventive as well as a curative treatment [86].

Hsps also play a role in the body's defense against cancer and currently
represent a preferred target for the development of cancer therapeutics. Research
on the understanding of the immune response to cancer has demonstrated the
involvement of some members of the Hsps family in inducing specific protection
against cancer. The importance of molecular chaperones in the recognition by the
immune system of tumor cells and the subsequent regression of tumors has been
demonstrated in animal models [87,88]. Some Hsps (Hsps 90 Grp94 and Hsps 70)
have been detected on the surface of tumor cells where they could activate the
immune response. These observations first led to the conclusion that they
represented antigens recognized by the immune system. It was thus demonstrated
that tumor-infiltrating T cells were able to recognize cells expressing Hsps 70, thus
suggesting that these specific T cells could support the local antitumor cellular
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response [89]. Another group of studies suggests that Hsps 70 and Hsps 90
participate in the antitumor immune response as carriers of tumor antigen peptides
and not as antigens themselves [90].

1.4.4.3 Complement-derived immunostimulants (CDI)
The complement system was discovered in the late 1890s. It is described
as a serum thermolabile component, which has antimicrobial properties, capable
of complementing the action of antibodies. Since then, knowledge has evolved,
and it is now established that this system is an integral part of the innate immune
system. This system refers to a set of serum proteins that play a crucial role in
innate immunity: allowing the host to defend against pathogens, participating in the
elimination of their cells under the condition of apoptosis. On the surface of
apoptotic cells or the pathogen, the complement system can be cascaded in three
ways: the classical pathway, the lectin pathway, or the alternative pathway. These
three pathways converge to result in the activation of the complement system,
which results in the release of several biologically active peptide fragments C3a
C4a, and C5a called anaphylatoxins that have diverse biological functions. These
fragments are biologically active cleavage products of the more abundant
complement proteins C3, C4 and C5, respectively. Apart from their direct action,
each of these pathways can induce inflammatory responses and modulate innate
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and adaptive immune responses leading to the elimination of pathogens, immune
complexes, and apoptotic cells [91,92].

One of the biological consequences of the activation of the complement
system is the release of C3a, C4a, and C5a cationic peptides. Initially, C5
convertase from the classical (C4b2a3b), lectin (C4b2a3b) or alternative
(C3bBb3b) pathways cleaves C5 into C5a and C5b. C5a remains in the fluid phase
and C5b associates rapidly with C6 and C7 and inserts into the membrane [92].
C5a generated in the lytic pathway has several potent biological activities. It is the
most potent anaphylatoxin. In addition to the ability to induce an anaphylactic
shock, C5a intervening in the inflammatory response in causing contraction of the
muscles, vasodilatation, and the vascularization of vascular permeability. The
properties of anaphylatoxin C5a may be partially inhibited or controlled after
cleavage of carboxy-terminal arginine by serum carboxypeptidase leading to the
generation of C5a-desarg [93].

1.4.4.3.1 The structure and functions of C5a
Anaphylatoxin C5a is a polypeptides molecule that is composed of 74
amino. NMR spectroscopy proved that the molecule is composed of four helices
and connected by peptide loops with three disulphide bonds between helix IV and
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II, III. There is a short 1.5 turn helix on N terminus, but all agonist activity take place
in the C terminus.C5a is rapidly metabolized by a serum enzyme carboxypeptidase
B to a 72 amino acid form C5a des-Arg without C terminal arginine [94].

Of the three anaphylatoxins, C5a is more potent and binds to at least two
receptors C5aR (CD88) and C5L2. The functional role of C5L2 is enigmatic. C5a
is a 74 amino acid peptide with pleiotropic biological functions including smooth
muscle contraction, vascular permeability, mast cell degranulation, leukocyte
chemotaxis and attraction (Figure 1.1) [95]. Early studies involving complement
mediated immune regulation showed that C5a potentiates antibody and antigeninduced T cell proliferative responses in vitro possibly through activation of T
helper cells [96]. Direct stimulation of mouse and human dendritic cells by C5a
activates them as demonstrated by increased expression of MHC class II,
upregulation of co-stimulatory molecules such as CD80, CD86, CD40 and CD54,
and secretion of cytokines of Th1 phenotype [97, 98]. C5a-mediated stimulation of
DCs also decreased intracellular production of cAMP, which is a negative regulator
of DC activation and function [98]. Furthermore, C5a interaction with C5aR
activates PI3K, ERK1/2, NF-kB signaling pathways in DCs, which positively
regulate antigen uptake, presentation and secretion of proinflammatory cytokines
by DCs [97,98]. C5a was also shown to exhibit both synergistic as well as
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antagonistic crosstalk with toll like receptors (TLRs) in functional modulation of
DCs [97,98]. C5a decreased TLR4 mediated IL-12 secretion by DCs, but
significantly increased secretion of other Th1 cytokines and CXC16 involved in NK
cell activation.

C5a-C5aR interactions were shown also to be essential for generation of
protective anti-viral CD8+ T cells. In contrast, genetic ablation or pharmacologic
blocking of C5aR signaling predominantly generated of Th2 and regulatory T cell
responses [99]. Furthermore, previous studies found that blocking C5a-C5aR
interactions also impaired the ability of immune system to generate memory CD4+
T cells [100]. Recent evidences also found that DCs stimulated with recombinant
C5a showed increased expression of multiple co-stimulatory molecules, migration
to the draining lymph nodes and strong interaction with antigen-specific naïve T
cells.

Besides immunostimulatory properties that promote antigen presentation
and functional immune responses, C5a also possesses highly inflammatory
properties. C5a is known to be the most potent mediator of local and systemic
inflammatory responses and causes multiple immunological effects such as
activating and recruiting neutrophils, induce spasmogenesis, increase vascular
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permeability and stimulate the release of secondary inflammatory mediators from
a variety of cell types (e.g., leukocytes and macrophages). Anaphylatoxin C5a is
also a potent chemotactic agent and release at the site of the lesion C5a causes
the release of histamine by the mast cells, the production of superoxide anions
and the release of hydrolytic enzymes by the neutrophils and promotes the
phagocytosis by the macrophages. By increasing the release of toxic proteins and
oxygenated reagents, C5a also activates eosinophils. Moreover, the stimulation of
macrophages by C5a results in the secretion of interleukin 1 (101).

1.4.4.3.2 Development of EP54 and EP67
C5a consists of highly ordered helical N-terminus (1-63) responsible for
recognition and binding of C5aR and highly flexible disordered C-terminus (64-74)
that exists as a finger-like projection from N-terminus (Figure 1.2) core responsible
for transducing biological signal [102]. Decapeptides possessing the essential
conformational features of C-terminus region of C5a showed full agonist activity
compared to natural C5a. Conformationally biased, response-selective agonist of
C5aR, EP54 (YSFKDMPLaR) was synthesized by amino acid residue modification
of C-terminus region of C5a (65-74). EP54 retained C5a-like immunostimulatory
properties as demonstrated by 5% of C5a-like induction of smooth muscle
contraction but was devoid of C5a-like inflammatory properties as demonstrated
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by only 0.1% of C5a’s ability to induce mast cell degranulation. The unique
structural and conformational features were shown to be well accommodated by
C5aRs on antigen presenting cells such as DCs and macrophages, but not by
C5aRs expressed on neutrophils. Furthermore, these conformational features
increase stability of EP54 from proteolytic degradation by serum carboxypeptidases. Additional modification of EP54 by introducing N-methylation
generated EP67, which increased response-selectivity towards C5aR and reduced
activity towards neutrophils up to 3000-fold compared to EP54 [103].
1.4.4.3.3 Vaccine Adjuvant Properties of EP54 and EP67
EP54 and EP67 were successfully used as adjuvants to generate antigenspecific humoral and cellular immune responses. Mice immunized with EP54
containing MUC1-constructs generated antibodies with class switched isotype,
which were able to bind to MUC1- expressing cancer cell lines. EP54 and MUC1CTL epitope containing vaccines also generated functional antigen specific
cytotoxic T cell responses [102]. Mice and rats immunized with EP67-conjugated
protein vaccines generated Th1-type humoral immune responses. Older mice
immunized with EP67 conjugated to a model protein antigen ovalbumin were also
able to generate higher antibody responses and Th1-type isotype switching which
were not observed when a toll like receptor (TLR) ligand CpG or alum were used
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as adjuvants [104]. The vaccine adjuvant properties of EP54 and EP67 in
generating protective adaptive immune responses were shown demonstrated in
various animal species (Table 1.2). EP54 and EP67 have shown to increase
antigen processing and presentation capacity, and induced release of Th1 type
cytokines by C5aR-bearing APCs [105].
Furthermore,

EP67

was

shown

to

reduces

Methicillin-Resistant

Staphylococcus aureus (MRSA) skin lesions. Subcutaneous administration of
EP67 (250 µg), but not inactive scrambled EP67 or PBS vehicle, significantly
reduced lesion size and recoverable CFU counts in outbred CD1 mice with dermal
infections of MRSA (TCH1516 USA 300). These host-directed anti-MRSA effects
are C5aR/CD88-dependent since they were not seen in C5aR knockout mice
(CD88-/-). EP67 induced the recruitment of essential neutrophils

and

macrophages to the lesion site through cytokine/chemokine release from C5aRbearing APCs in the lesion zone [106].
Moreover, administration of EP67 (200 µg) in the area of a MRSA (USA 300
LAC) biofilm infection around an implanted subcutaneous catheter resulted in a
significant reduction of recoverable CFU counts within the biofilm and surrounding
tissue. This effect was seen within 24 hrs of administration of EP67 and was
sustained for up to 5 days post-administration. It was also shown that EP67
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increased the recruitment of macrophages to the biofilm infection and induced the
release of IL-12p40, CCL5, IL-17, IL-1β, and INFγ in the biofilm. These effects
were not seen by the administration of inactive scrambled EP67 or vehicle (PBS)
[107].
Furthermore, pulmonary delivery of EP67 was also found to protects against
sub-lethal and lethal Infections of Influenza A. Intranasal insufflation of EP67 (25
µg in 30 µL) 24 hrs prior to influenza infection significantly reduced loss of body
weight upon infection relative to mice that received no EP67 or vehicle (PBS) only.
Likewise, infected mice that received EP67 (25 µg in 30 µL) 24 hrs post-infection
showed a significant reduction in the loss of body weight relative to mice that
received no EP67 or PBS only. This pulmonary administration of EP67 resulted in
a significant influx of neutrophils, alveolar macrophages, dendritic cells, and
natural killer cells in the bronchoalveolar lavage (BAL) fluids of both uninfected and
infected mice. BALs from mice treated with EP67 also showed significantly higher
amounts of IL-6, GM-CSF, KC (the murine equivalent of IL-8), IL1β, IL12p70, and
MIP-1. These cellular and cytokine/chemokine influxes are consistent with the
prophylactic and therapeutic effects of EP67 described above as well as the ability
of EP67 to overcome the inherent immune suppressive effects of influenza
infection. These effects were not observed in mice administered scrambled EP67
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of PBS vehicle. Finally, intranasal insufflation of EP67 (240 µg in 30 µL) 24 hrs
after administration of a lethal dose of influenza protected all mice (100% survival)
up to 30 days. All untreated mice were dead 11 days post-infection [108]. The
results summarized above underscore the capacity of the topochemical features
expressed in EP67 to be selectively accommodated by C5aRs expressed on APCs
vs. C5aRs expressed on neutrophils and, consequently, the ability to selectively
activate C5aR-bearing APCs for the induction of host innate immunity, which
reduces normal/resistant bacterial and viral infections. Thus, EP67 can be used as
a template from which can be generated EP67 analogs even more effective in
C5aR-bearing APC engagement and activation. The availability of such analogues
would usher in the therapeutic concept of host-directed immunotherapy.
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Figure 1.1 Role of Complement C5a in host defense and homeostasis [Adapted
from 95].
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Figure 1.2 Structure of human C5a
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Immunostimulants

Origin

Mechanism

Clinically

of action

application use

Stimulates

Bladder cancer,

macrophages

TB

Microbiallyderived
immunostimulants

Live mycobacteria
BCG

Stimulates
natural killer
Group A streptococcus

cells,

Picibanil

Lymphangiomas
pyrogenes

macrophages
and
lymphocytes
Stimulates

Krestin

CD8+ T cells

Gastric and other

and natural

cancers

Fungal Polysaccharide

killer cells
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Stimulates
Lentinan

Fungal Polysaccharide

Gastric cancer
macrophages

Klebsiella pneumoniae

Stimulates

Chronic/recurrent

extraction

macrophages

infections

OM-85 (Broncho-

Lysate of eight bacterial

Stimulates

Chronic/recurrent

Vaxom)

pathogens

macrophages

infections

Biostim

Induce and
activates BPneumococcal

cell-

Chronic/recurrent

polysaccharides

dependent

infections

Pneumovax 23

immune
response
Meningococcal (Groups
Menactra

Activates B

Chronic/recurrent

and T cells

infections

A, C, Y and W-135)
Polysaccharide

Thymus-derived
immunostimulants
Stimulates T
Cancers and
Thymostimulin

Thymic peptide extract

cell
infections
maturation
Stimulates T
Cancer and

Thym-uvocal

Thymic peptide extract

cell
AIDS
maturation
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Thymomodulin

Thymic peptide extract

Stimulates T

Infections,

cell

allergies and

maturation

malignancies

Exogenous
Cytokines
immunostimulants
Recombinant granulocyte
Stimulate
filgrastim

colony-stimulating factor

Neutropenia
bone marrow

(G-CSF)
Reduce
neuron
inflammation,
increase the
Recombinant Interferon

production of

Multiple sclerosis

β-1a

nerve growth

(MS)

Interferon β-1a

factor and
improve
neuronal
survival
chronic
Recombinant Interferon γInterferon γ-1b

granulomatous
1a
disease (CGD)
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upregulates
the
expression of
MHC I
Recombinant Interferon

proteins,

Cancers and

α-n3

enhances the

infections

Interferon α-n3

activation of
CD8+ T cells,
and stimulate
macrophages
Metastatic renal
Activates T
Aldesleukin

Recombinant IL-2

cells, natural
killer cells

Oprelvekin

cell carcinoma
and metastatic
melanoma

Stimulate the

Myeloid

bone marrow

malignancies

Recombinant IL-11
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Chemically
modified
immunostimulants
stimulates
chemotherapymacrophages,
induced
Romurtide

Muramyl dipeptide

increased
leukopenia, bone
production of
marrow recovery
neutrophils
Cancers,

Pentapeptide (Arg–Lys–

Stimulate T

rheumatoid

Asp–Val–Tyr)

cells

arthritis and

Thymopentin

infections
Salt of acetamidobenzoic
Inosine pranobex

Stimulate T

Infections and

cells

cancers

acid and
dimethylaminoisopropanol

Table 1.1 Clinically licensed immunostimulants (Adapted from [2])
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Vaccine Construct

Route

Immune Response

Ref

Peptide epitope from MUC1

i.p.

↑IgG2b, IgG2c and IgM

[102]

glycoprotein conjugated to EP54
CTL peptide epitope derived from

Abs
s.c

Ag-specific CD8+ CTL

Hepatitis B surface Antigen

responses against murine

(HBsAg) conjugated to EP54

P815S target cells

Nicotine hapten conjugated to

[109]

i.p.

Nicotine-specific Abs

[110]

s.c /i.p.

Meth-specific Abs in sera

[111]

i.p.

OVA-specific Th1-like Ab

[112]

EP54
Methamphetamine (meth) hapten
conjugated to EP54
OVA conjugated to EP67

class switch and OVAspecific proliferative
responses in splenocytes
OVA conjugated to EP67

i.p.

↑ Ag-specific humoral

[113]

rPrp1,a protein from cell wall of

i.p.

↑ humoral responses

[113]

coccidioides conjugated to EP67

compared to alum and
CpG

Peptide epitope derived from gp70
glycoprotein conjugated to EP54
and EP67

s.c

↑ CTL responses and
↓RAW117-H10 growth

[114]
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Live spores of attenuated vaccine

s.c

strain of Coccidioides posadasii

↑ IgG1, IgG2a, Th1, and

[115]

Th17 immune responses

conjugated to EP67
CTL peptide epitopes from MCMV
PP89 and M84 conjugated to EP67

i.n.

↑ CTL responses
↓ MCMV titers

Table 1.2 Vaccine adjuvant properties of EP54 and EP67

[116]
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CHAPTER 2

Hypothesis and Specific Aims
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2.1 Research Objectives and Hypotheses
There is an unmet need for safe and efficacious approaches to treat
infections through the stimulation of systemic and mucosal innate immunity with
little toxicity. One approach is to stimulate innate immune responses with a safe
and effective immune stimulatory molecule. Such “host-directed immunotherapy”
will stimulate the body’s inherent first line of defense against infections while
exerting few/no mutational pressure on the infecting pathogen. Our group
previously has shown the potential of host-directed immunotherapy against viral
infections in mice by the administration of our lead immune stimulatory candidate
EP67.

The decapeptide EP67 is a novel host-derived adjuvant based on the Cterminal of C5a that selectively activates antigen presenting cells (APCs)monocytes, macrophages, and dendritic cells over neutrophils. In contrast to
C5a65-74 from the C5a parent molecule, EP67 has topographical features that are
well accommodated by C5aRs expressed on (APCs), but not C5aRs neutrophils.
Thus, EP67 induces host innate immune responses against normal and resistant
infections via engagement of C5aR-bearing APCs with little/no inflammatory sideeffects associated with the direct activation of neutrophils.
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The Pro residue at position 7 (Pro7) is critical for the potency and selectivity
of EP67. It was placed in this position to force an extended conformation at the
carbonyl carbon between the  and  bonds in the Met backbone to its Nterminus, a feature that was found to be biologically important from SAR studies
with the previous analog of EP67, EP54. The Pro residue, however, undergoes
cis/trans isomerization that leads to conformers of EP67 in solution, making it
unclear whether cis/trans isomerization is important to the biological properties of
EP67 or if one conformer is more effective than the other. What is clear is that the
conformational influence of Pro at this position is important for the activity and bioselectivity of EP67. Our long-term goal is to increase the potency and efficacy of
EP67 to improve host-directed immunotherapy and vaccine applications. The
overall objective of this proposal is to generate analogs of EP67 with increased
potency, efficacy, and bio-selectivity. Our central hypothesis is that replacing Pro
in position 7 with structurally diverse residues that are likely to shift the cis/trans
conformer equilibrium or lock the conformation in either a cis or trans orientation
increases the potency and APC-selectivity of EP67.
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2.2 Specific Aims

Specific Aim 1. Synthesize a series of EP67 analogs with residue substitutions
for Pro at position 7. As noted above, our goal is to generate a series of EP67
analogs to better understand the conformational influence of Pro in the Met-ProMeLeu triad region of EP67 and to increase the structural diversity within this
biologically important core of EP67 with the objective of increasing the potency
and bio-selectivity of this unique innate immune stimulatory decapeptide.

Specific Aim 2. Determine analog potency and bio-selectivity in C5aR-bearing
human phagocytes (monocytes, monocytes-derived macrophages (M0-MDM),
monocytes-derived

immature

DCs

(MDDC),

and

C5aR-bearing

human

neutrophils. EP67 analogs generated in Aim 1 will be assessed for their potency
to C5aRs on human monocytes, M0-MDM, MDDC and neutrophils, as measured
by cytokine release (IL-1β, IL-6, and TNF-α) from monocytes, M0-MDM, MDDC
and myeloperoxidase (MPO) release from neutrophils, and from these potency
assays, their bio-selectivity relative to EP67 and natural C5a will be determined.
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CHAPTER 3

MATERIALS AND METHODS
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3.1 Peptide synthesis, purification, and characterizations
With the assistance of an AAPPTEC Apex 396 Synthesizer, all peptides
were assembled on preloaded Fmoc-Arg(pbf)-Wang resin using Fmoc-amino acid
derivatives

and

N-(dimethylamino)-1H-1,2,3-triazolo-[4,5-b]pyridin-1-

ylmethylene]-N-methylmethanaminium hexafluorophosphate N-oxide (HATU) in
the presence of excess DIEA. Peptides were cleaved from the resin and freed of
sidechain protecting groups by stirring the peptide-resin in a mixture of TFA
(87.5%), phenol (5%), water (5%), and triisopropylsilane (2.5%) for 2h at room
temperature [117,118]. All peptides were subjected to analytical reversed-phase
HPLC employing three different columns under the same gradient elution
conditions. The three columns were an ACE 5 C18-300 column (250 x 4.6 mm, 5
µm, 300 Å pore size, catalog number ACE-221-2546), ACE 5 Phenyl-300 column
(250 x 4.6 mm, 5 µm, 300 Å pore size, catalog number ACE-225-2546) and ACE
5 CN-300 column (250 x 4.6 mm, 5 µm, 300 Å pore size, catalog number. ACE224-2546) from MAC-MOD Analytical Inc. (Chadds Ford, PA). Solvent A was water
containing 0.1% trifluoroacetic acid (TFA, v/v) and solvent B was a mixture of
acetonitrile and water (3/2, v/v) containing 0.1 % TFA. Peptides were eluted from
the columns by increasing the percentage of solvent B from 5 to 100% over 50
minutes and column effluent was continuously monitored at 214 nm. Peptide
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masses were obtained from the Mass Spectrometry and Proteomics Core Facility
at the University of Nebraska Medical Center. Masses were measured on an
Orbitrap Fusion Lumos from ThermoScientific (Waltham MA) and with ≤ 0.5 ppm
error. Amino acid compositions of all peptides were provided by the Protein
Structure Core Facility at the University of Nebraska Medical Center. Samples
were subjected to vapor-phase hydrolysis in constant boiling 6M hydrochloric acid
for 24 hours prior to being loaded on to a Hitachi 8800 Amino Acid Analyzer.

3.2 De novo peptide structures
PEP-FOLD was used to generate the initial conformation of C5a 6574.

Analogs of C5a65-74 were generated in YASARA and refined for 500 ps using

the built-in md_refine macro. Each refined structure was then used in a 50 ns
molecular dynamics (MD) simulation. All molecular dynamics simulations and postanalysis used Desmond as bundled with the Schrodinger software suite. Each
peptide was placed in a cubic box with periodic boundaries. No dimension of the
box was allowed closer than 12 Angstroms to allow the peptides room to unfold.
The box was filled with TIP4P water and neutralized by adding the appropriate Na+
or Cl- ions. Salt concentration in the box was set to 0.05 M NaCl. All simulations
first used Schrodinger’s built in relaxation protocol before the main MD run. The
main 50 ns MD run was an NPT ensemble with temperature at 298K and pressure
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at 1 atm. Noose-Hoover chain and Martyna-Tobias-Klein were the thermostat and
barostat methods, respectively. The average structure of the major cluster of each
trajectory was then extracted for comparison in YASARA [119,120].
3.3 Isolation of human monocytes and neutrophils from human whole blood
Fresh whole blood [1 unit = 450 mL] was drawn from human healthy male
donors (aged 19–40 years) into vacutainer bags (Research Innovative, USA)
containing EDTA. CD14+ monocytes [165 mL of blood/donor] were isolated by
MACS® technology using CD14 MicroBeads (Miltenyi Biotec, Germany) according
to the manufacturer's protocol. Isolated monocytes [1x106 cells/well] were cultured
into 24-well plates, and allowed to adhere [2 hrs] in complete culture medium
(CCM) (RPMI 1640, 2 mM L-glutamine, 1% autologous plasma, 1 mM sodium
pyruvate, 0.1 mM non-essential amino acids, 1x vitamins, 100 U/mL penicillin G,
100 g/mL streptomycin sulfate (Invitrogen, Carlsbad, CA) [1 mL/well] and
incubated at 37 °C and 5% CO₂. Non-adherent cells were discarded, and the
adherent cells were washed carefully twice with sterile D-PBS (“PBS” without Ca2+
or Mg2+, GE Healthcare Life Sciences: SH30028.02) [1 mL] [120,121].
Neutrophils were also isolated from same donors [10 mL of blood/donor]
using the MACSxpress® Whole Blood Neutrophil Isolation Kit, a MACSmix™ Tube
Rotator, and a MACSxpress Separator (Miltenyi Biotec, Germany) according to the
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manufacturer's protocol. Isolated neutrophils [1x106 cells/well] were cultured into
24-well plates in CCM [1 mL] and incubated at 37 °C and 5% CO₂. Non-adherent
cells were discarded, and the adherent cells were washed carefully twice with
sterile D-PBS [123]. The purity of the isolated monocyte and neutrophil was
determined by labeling cells with CD14- PE-Vio615, CD-15APC, and CD-16PE
human antibodies (Miltenyi Biotec, Germany) before and after separation, and
analyzed by flow cytometry. Briefly, isolated cells [1x106] were resuspended in cell
staining buffer (BD Biosciences) [100 µL] and indicated antibodies [5 µL/each
antibody]. Cells were mixed and incubated in the dark in the refrigerator [2−8 °C,
10 min.]. Then, cells were washed by adding staining buffer [1 mL] and pelleted
[300 RCF, RT, 10 min.]. The supernatant was completely aspirated, and cell pellets
were resuspended in FACS staining buffer [0.5 mL] for analysis by cytometry. Cells
were analyzed on a BD LSR II flow cytometer (Becton and Dickinson, La Jolla, CA)
with BD High Throughput Sampler. Flow cytometer was compensated using single
stained cells, maximum number of events were acquired and analyzed by FlowJo
software (Tree Star, Ashland, OR, USA) [124,125].

65

3.4 Generate unpolarized human monocyte-derived macrophages (M0MDM), and human monocyte-derived dendritic cells (MDDC)
Generation of unpolarized human monocyte-derived macrophages (M0MDM) was done by culturing monocytes [1×10⁶ cells/well] in CCM [1 mL]
containing recombinant human M-CSF (Miltenyi Biotec) [50 ng/mL] in 24 well
plates. On day 3, half media [0.5 mL] from each well was carefully removed and
replenished with CCM containing rhM-CSF. After the differentiation, the cell
supernatants were completely removed by gentle aspiration and cells were
washed once with warm sterile PBS [126-128].

To generate human monocytes-derived immature dendritic cells (MDDC),
isolated monocytes [1×10⁶ cells/well] were cultured in CCM [1 mL] supplemented
with recombinant human IL-4 [50 ng/mL] and recombinant human GM-CSF [160
ng/mL] (Miltenyi Biotec) in 24-well culture dishes. On days 3 and 6, half of the
volume [0.5 mL] was gently aspirated from each well and replenished with CCM
containing GM-CSF and IL-4 [128-130]. The morphology of differentiated cells
(macrophages as well as immature Mo-DCs) were analyzed by placing cells in a
24-well plate and allowed to sediment. Images of the cells were captured using a
light microscope with phase-contrast at a 400× magnification.
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3.5 Determine the potency of EP67 analogs
Analog potency was determined by measuring the half-maximal effective
concentration (EC50). EC50 values for each analog were determined in two
separate assays: cytokine release from human mononuclear phagocytes (human
monocytes, M0-MDM, and MDDC) and myeloperoxidase (MPO) release from
human neutrophils. Full dose-response curves were generated in each
experiment, and the EC50 values were determined. Briefly, monocytes, M0-MDM,
and MDDC [1x106 cells/well] were incubated in the presence of serial
concentrations of C5a desArg, EP54, EP67, and EP67 analogs in standard cell
culture conditions for 24 hrs. Supernatants were collected and assayed for the
presence and amount of the IL-1β, IL-6, and TNF-α (BioLegend, USA) using
standard ELISA methods [102,131].

In human neutrophils, the release of the proteolytic enzyme MPO was
measured. Briefly, neutrophils were incubated in the presence of serial
concentrations of C5a desArg, EP54, EP67, and EP67 analogs in standard cell
culture conditions for 24 hrs. Supernatants were collected and assayed for the
presence and amounts of MPO using standard ELISA [103,131].
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3.6 Determine the bio-selectivity of EP67 analogs

Analog selectivity for cytokine release (IL-6, and TNF-α) from phagocytes
cells (monocytes, M0-MDM, and MDDC) vs. MPO release from neutrophils were
determined by the following equation:

Selectivity = antilog[(-∆phagocytes) – (-∆neut)]

, where ∆ is the log potency ratio (pD2 C5a – pD2 analog) and pD2 = –logEC50. The
“selectivity” of natural C5a desArg were set at value of 1 using this equation since
it is equipotent in both cytokine release from monocytes and MPO release from
neutrophils. Thus, differences in the potencies between these two C5aR-bearing
cells can be assessed relative to C5a desArg; i.e., the greater the value from the
above equation, the greater the selectivity relative to C5a desArg. This is the
pharmacologically accepted means of determining selectivity between two
compounds and was used by us to determine the selectivity of EP67 for
engagement and activation of C5aR-bearing phagocytes over that of C5aRbearing neutrophils (131).
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3.7 Compare the IL-6 and TNF-α cytokine release rates from human
monocytes,

M0-monocyte-derived

macrophages,

and

immature

monocyte-derived dendritic cells.
Human monocytes (MC), M0-monocyte-derived macrophages (M0MDM), and immature monocyte-derived dendritic cells (MDDC) were prepared
from the whole blood of healthy, young human adult male donors. Cell types
were treated with the calculated EC50 of human C5a desArg pooled from the
blood of multiple donors (black closed circles), 1st-generation EP54 (black
closed squares), 2nd-generation EP67 (black closed triangles), [Cha 7]EP67
(red open circles), [Leu8]EP67 (green open squares), or [Cha 7, Leu8]EP67
(blue open triangles). At the indicated time points, average concentrations of
IL-6 or TNF-α released into cell culture media by human monocytes, M0-MDM,
and MDDC were determined by ELISA.
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CHAPTER 4

RESULTS AND DISCUSSION
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4.1 Replacing Pro7 with cyclohexylalanine and/or N-methyl Leu8 with Leu
selectively affects the potency and efficacy of EP67 in human
mononuclear phagocytes
We originally proposed that Pro7nme-Leu8 increases the potency and
selective activation of mononuclear phagocytes vs. neutrophils vs. EP54 by
extending the peptide backbone. Thus, we wanted to identify amino acid
substitutions that would eliminate cis/trans isomerization of EP67 while still
extending the peptide backbone. We hypothesized that substituting an amino acid
that eliminates cis/trans isomerization and has a bulky side chain such as
cyclohexylalanine (Cha) will extend the peptide backbone of EP67 to a similar
extent as Pro7nme-Leu8 without adversely affect potency and efficacy. RMSD
traces from de novo peptide structure prediction showed long periods of low RMSD
to the major cluster, suggesting C5a 65-74 maintains an alpha-helical backbone
conformation throughout most of the simulation (Figure 4.1). In contrast, although
[Cha7Leu8] EP67 is masked in the major cluster view, RMSD traces indicate that
amino acid substitutions introduced to EP67 and EP67 analogs greatly increase
the flexibility of C5a65-74. This increased flexibility is more similar to the disordered
structure of C5a65-74 observed by MMR when part of native C5a, although a short
helix was observed. The similarity between C5a65-74 and [Leu8] EP67 RMSD traces
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suggests [Leu8] EP67 best preserves the predicted alpha-helical backbone of
C5a65-74. We hypothesized that nme would not be required to extend the peptide
backbone with Cha
To determine if replacing Pro7 and/or N-methyl Leu8 with amino acids that
induce similar structural changes will affect the potency and efficacy of EP67 in
human mononuclear phagocytes, we first replaced Pro 7 with Cha ([Cha7]EP67),
nme-Leu8 with native Leu ([Leu8]EP67), or Pro7 and nme-Leu8 with Cha and native
Leu, respectively ([Cha7Leu8]EP67) (Table 4.1), determined purity (Table 4.2)
(Figure 4.2) and molecular mass (Table 4.3) (Figure4.3), and confirmed the
amino acid sequence (Table 4.4) of each peptide. We then prepared human
CD14+ / CD14+CD16+ monocytes (MC), unpolarized human monocyte-derived
macrophages (M0-MDM), and human monocyte-derived dendritic cells (MDDC)
from the whole blood of healthy, human adult male donors (Figure 4.4) and
compared dose-dependent secretion of IL-1β, IL-6, and TNF-α after treating with
pooled human C5a desArg (parent molecule), EP54 (1 st generation ADI), EP67
(2nd-generation ADI), or EP67 analogs for 24 h (Figure 4.5). We used “classical”
CD14HI MC because they represent 85% to 95% of human monocytes and will
include the “intermediate subset” CD14+CD16+ MC and potentially the “nonclassical” CD14LOCD16HI MC 1, unpolarized M0-MDM (Day 6 MCF) because they
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are similar to tissue resident macrophages from healthy tissues, and MDDC (Day
7 GM-CSF/IL-4). Mononuclear phagocytes (monocytes, macrophages, and
dendritic cells) are critical immune sensors in the body that play a key role in
initiating and guiding innate and adaptive immunity. Acute inflammation augments
innate and adaptive immune responses and is driven by the secretion of three
major proinflammatory cytokines: IL-1β, IL-6, and TNF-α. We compared dosedependent secretion of IL-1β, IL-6, and TNF-α because they are the major early
pro-inflammatory cytokines that drive acute inflammation in support of innate and
adaptive immune responses and are, consequently, good surrogate markers for
the activation of mononuclear phagocytes.
Sigmoidal dose-responses curves were observed for IL-1β secretion from
MC, M0-MDM, and MDDC over the concentration range of C5a desArg (Figure
4.6), whereas IL-1β was not detected after treatment with up to 1 mM EP54, EP67,
or EP67 analogs (not shown). In contrast to IL-1β, sigmoidal dose-response curves
were observed for IL-6 and TNF-α secretion from MC, M0-MDM, and MDDC over
the concentration ranges of C5a desArg (black circles), EP54 (black squares),
EP67 (black triangles), and EP67 analogs (colored open symbols) (Figure 4.5).
This suggests the current ADI do not stimulate the secretion of one or more
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cytokines and, possibly, chemokines from human mononuclear phagocytes that
are normally stimulated by the C5a/C5a desArg parent molecule.
The EC50 for EP67 (Figure 4.7 A, black triangles) ranged from 14.6- (TNFα from MC) to 89.5-fold greater (IL-6 from MDDC) than C5a desArg (Figure 4.7 A,
black circles) (Table 4.5). Furthermore, the EC50 for EP67 (Figure 4.7 A, black
triangles) was similar to the EC50 for EP54 (Figure 4.7 A, black squares), with the
exception of TNF-α secretion from MC (35% less) (121 ± [-0.2,+0.3] [95% CI] vs.
186 [-0.2,+0.3] nM) and IL-6 secretion from M0-MDM (47% less) (167 ± [-0.3,+0.3]
[95% CI] vs. 317 [-0.9,+1] nM) (Table 4.5). The EMAX for EP54 ranged from 24 to
47% lower (Figure 4.7 B, black squares) than pooled human C5a desArg (Figure
4.7 B, black circles), whereas and the EMAX for EP67 (Figure 4.7 B, black triangles)
ranged from 6 to 27% lower depending on the cytokine and mononuclear
phagocyte (Table 4.5). Thus, EP54 and EP67 are both generally partial agonists
for activating human mononuclear phagocytes. The EMAX for EP67 (Figure 4.7 B,
black triangles) was 23.6% to 34% greater than the E MAX for EP54 (Figure 4.7 B,
black squares) also depending on the cytokine and mononuclear phagocyte. Thus,
the potency of EP67 is similar or greater than EP54 depending on the secreted
cytokine and human mononuclear phagocyte, whereas the efficacy of EP67 for IL6 and TNF-α secretion is greater than EP54 in human mononuclear phagocytes.
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[Cha7]EP67 (Figure 4.7 A, red open circles) did not affect the EC50 of EP67
(Figure 4.7 A, black triangles) for IL-6 and TNF-α from MC, decreased EC50 for IL6 (29%) but not TNF-α from M0-MDM, and did not affect the EC50 for IL-6 and TNFα from MDDC. In contrast, [Leu8]EP67 (Figure 4.7 A, green open triangles) did not
affect the EC50 for IL-6 and TNF-α from MC, M0-MDM, or MDDC. In contrast,
[Cha7Leu8]EP67 (Figure 4.7 A, blue open triangles) did not affect the EC50 for IL6 and TNF-α from MC, decreased the EC50 for IL-6 (31%) without affecting the
EC50 for TNF-α from M0-MDM, and did not affect the EC50 for IL-6 but decreased
the EC50 for TNF-α (39%) from MDDC. Thus, [Cha7]EP67 selectively increases
potency in M0-MDM without affecting potency in MC or MDDC, [Leu8]EP67does
not affect potency in MC, M0-MDM, or MDDC, and [Cha7, Leu8] selectively
increases potency in M0-MDM and MDDC without affecting potency in MC
compared to EP67.
[Cha7]EP67 (Figure 4.7 B, red open circles) did not affect EMAX of EP67
(Figure 4.7 B, black triangles) for IL-6 but increased EMAX for TNF-α (9.5%) from
MC and decreased EMAX for IL-6 and TNF-α from M0-MDM (9.5%, 16%) and
MDDC (5.2%, 16.6%). [Leu8]EP67 (Figure 4.7 B, green open squares) decreased
EMAX for IL-6 (9.3%) without affecting EMAX for TNF-α from MC, did not affect EMAX
for IL-6 but decreased EMAX for TNF-α (23%) from M0-MDM, and, unexpectedly,
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greatly increased EMAX for IL-6 and TNF-α from MDDC (41%, 45%) to levels similar
(IL-6) or greater (TNF-α) than C5a desArg (Figure 4.7 B, black circles). In contrast,
[Cha7Leu8]EP67 (Figure 4.7 B, blue open triangles) did not affect EMAX for IL-6
and TNF-α from MC, but decreased EMAX for IL-6 and TNF-α from M0-MDM (21%,
21%) and MDDC (16%, 10%), respectively. Thus, [Cha7]EP67 selectively
increases efficacy in M0-MDM and MDDC, [Leu8]EP67 selectively decreased
efficacy in MC and M0-MDM but significantly increases efficacy in MDDC, whereas
and [Cha7, Leu8]EP67 does not affect efficacy in MC but decreases in M0-MDM
and MDDC compared toEP67.
As a whole, these results indicate that, compared to EP67, (i.) [Cha7]EP67
does not affect potency but selectively increases efficacy in MC, selectively
increases potency but decreases efficacy in M0-MDM, and does not affect potency
but decreases efficacy in MDDC (ii.) [Leu8]EP67 does not affect potency in MC,
M0-MDM, or MDDC but selectively decreases efficacy in MC and M0-MDM and
greatly increases efficacy in MDDC and (iii.) [Cha7Leu8]EP67 does not affect
potency or efficacy in MC, selectively increases potency but decreases efficacy in
M0-MDM, and selectively increases potency but decreases efficacy in MDDC.
Thus, replacing Pro7 with cyclohexylalanine and/or N-methyl Leu8 with Leu affects
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the potency and efficacy of EP67 depending on the human mononuclear
phagocyte and secreted cytokine.
4.2 Replacing Pro7 with Cha and/or nme-Leu8 with Leu does not affect EP67
potency in human neutrophils but selectively decreases efficacy
To determine if replacing Pro7 with Cha and/or nme-Leu8 with Leu affects
the potency and efficacy of EP67 in human neutrophils (NP), we isolated
neutrophils from the whole blood of healthy, young human adult male donors by
using MACSxpress® Whole Blood Neutrophil Isolation Kit, a MACSmix™ Tube
Rotator, and a MACSxpress Separator (Miltenyi Biotec, Germany) (Figure 4.4)
then compared dose-dependent secretion of myeloperoxidase (MPO) from NP
after treating with pooled human C5a desArg, EP54, EP67, or EP67 analogs for
24 h (Figure 4.8). Sigmoidal dose-responses curves were observed for MPO
secretion from NP over the concentration ranges of C5a desArg, EP54, EP67, and
EP67 analogs (Figure 4.8 A).
The EC50 for EP54 (Figure 4.8 B, black squares) was 3000-fold greater
than C5a desArg (7 ± 1 nM [95% CI] vs. 21 [-3,+4] µM) in NP, whereas the EC50
for EP67 (Figure 4.8 B, black triangles) was 22,857-fold greater than C5a desArg
(Figure 4.8 B, black circles) (7 ± 1 nM [95% CI] vs. 160 [-17,+20] µM) (Table 4.6).
Furthermore, the EMAX for EP54 (Figure 4.8 C, black squares) was 1.7-fold less
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than C5a desArg (5.6 ± 0.2 [95% CI] vs. 9.3 ± 0.3 ng/mL), whereas the E MAX for
EP67 (Figure 4.8 C, black triangles) was 2.7-fold less than C5a desArg (3.5 ± 0.1
[95% CI] vs. 9.3 ± 0.3 ng/mL) (Table 4.6). The EC50 for EP67 was also 3-fold
greater than EP54 (160 [-17,+20] [95% CI] vs. 21 [-3,+4] µM) and the EMAX was
1.6-fold less than EP54 (3.5 ± 0.1 [95% CI] vs. 5.6 ± 0.2 ng/mL) (Table 4.6). Thus,
consistent with previous studies (131), the potencies and efficacies of EP54 and
EP67 are well below human C5a desArg and the potency and efficacy of EP67 is
less than EP54 in human neutrophils.
None of the EP67 analogs (Figure 4.8 B, colored open symbols) affected
the EC50 for MPO secretion from NP compared to EP67 (Figure 4.8 B, black
triangle). In contrast, [Cha7]EP67 (Figure 4.8 C, red open circle) and
[Cha7Leu8]EP67 (Figure 4.8 C, blue open triangle) decreased EMAX for MPO
secretion by 21% and 24%, respectively (Table 4.6), whereas [Leu8]EP67 (Figure
4.8 C, green open square) did not affect the EMAX compare to EP67 (Figure 4.8 C,
black triangle). Thus, replacing Pro7 with cyclohexylalanine and/or N-methyl Leu8
with Leu has no effect on the potency but selectively decreases the efficacy of
EP67 in human neutrophils.
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4.3 Replacing Pro7 with Cha and/or nme-Leu8 with Leu does not affect
selective activation of human mononuclear phagocytes over human
neutrophils
To determine if replacing Pro7 with Cha and/or nme-Leu8 with Leu
affects the selective activation of human mononuclear phagocytes over human
neutrophils, we compared the ability of EP54, EP67, or EP67 analogs vs.
pooled human C5a desArg to selectively stimulate secretion of IL-6 or TNF-α
from human monocytes (MC), unpolarized monocyte-derived macrophages
(M0-MDM), and monocyte-derived dendritic cells (MDDC) over secretion of
myeloperoxidase (MPO) from human neutrophils (NP) 24 h after treatment
(Figure 4.9). Selectivities of EP67 (Figure 4.9, black triangles) for stimulating
MC, M0-MDM, and MDDC over NP were 9- to 15-fold greater than EP54
(Figure 4.9, black squares) depending on cytokine and mononuclear
phagocyte. EP67 selectivity for stimulating human mononuclear phagocytes
over human neutrophils is greater than EP54.
None of the EP67 analogs (Figure 4.9, colored open symbols) affected
selectivities for stimulating IL-6 or TNF-α secretion from MC (Figure 4.9 A),
M0-MDM (Figure 4.9 B), or MDDC (Figure 4.9 C) over stimulating the
secretion of MPO from NP compared to EP67 (Figure 6C, black triangles)
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(Table 4.7). Thus, replacing Pro7 with cyclohexylalanine and/or N-methyl Leu8
with Leu does not affect the selective activation of human mononuclear
phagocytes over human neutrophils by EP67.
4.4 Replacing Pro7 with Cha and/or nme-Leu8 from the structure of EP67
does not affect kinetics of cytokine release from human mononuclear
phagocytes.
To next determine if replacing Pro7 with Cha and/or nme-Leu8 with Leu
affects the kinetics of cytokine release from human mononuclear phagocytes, we
compared the release of IL-6 and TNF-α from human monocytes, M0-MDM, and
MDDC 24 and 48 h after treatment with the EC50 of [Cha7,Leu8]EP67, human
C5a desArg, EP54, or EP67 (Figure 4.10). C5a desArg (black bars) had the
highest levels of IL-6 and TNF-α release after 24 h, whereas [Cha7, Leu8] EP67
(red bars), EP54 (green bars), and EP67 (blue bars) had the highest levels after
48 h. Thus, replacing Pro7 with Cha and/or nme-Leu8 with Leu from the structure
of EP67 does not affect the kinetics of cytokine release from human mononuclear
phagocytes.
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Figure 4.1 De novo structure of C5a desArg, EP54, EP67, and EP67 analogs.
PEP-FOLD was used to generate the initial conformation of C5a 65-74. Analogs of
C5a65-74 were generated in YASARA and refined for 500 ps using the built-in
md_refine macro. Each refined structure was then used in a 50 ns molecular
dynamics (MD) simulation. All molecular dynamics simulations and post-analysis
used Desmond as bundled with the Schrodinger software suite. Each peptide was
placed in a cubic box with periodic boundaries. No dimension of the box was
allowed closer than 12 Angstroms to allow the peptides room to unfold. The box
was filled with TIP4P water and neutralized by adding the appropriate Na+ or Clions. Salt concentration in the box was set to .05 M NaCl. All simulations first used
Schrodinger’s built in relaxation protocol before the main MD run. The main 50 ns
MD run was an NPT ensemble with temperature at 298K and pressure at 1 atm.
Noose-Hoover chain and Martyna-Tobias-Klein were the thermostat and barostat
methods, respectively. The average structure of the major cluster of each trajectory
was then extracted for comparison in YASARA.
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Figure 4.2 RP-HPLC chromatograms of EP67 and EP67 analogs.
Cha = cyclohexylalanine. Peptides were subjected to analytical reversed-phase
HPLC employing three different columns under the same gradient elution
conditions: an ACE 5 C18-300 column (250 x 4.6 mm, 5 µm, 300 Å pore size,
catalog number ACE-221-2546), an ACE 5 Phenyl-300 column (250 x 4.6 mm, 5
µm, 300 Å pore size, catalog number ACE-225-2546), or an ACE 5 CN-300 column
(250 x 4.6 mm, 5 µm, 300 Å pore size, catalog number. ACE-224-2546) from MACMOD Analytical Inc. (Chadds Ford, PA). Solvent A was ddH2O containing 0.1%
trifluoroacetic acid (TFA, v/v) and solvent B was a mixture of acetonitrile and
ddH2O (3/2, v/v) containing 0.1 % TFA. Peptides were eluted from the columns by
increasing the percentage of solvent B from 5 to 100% over 50 minutes while
column effluent was continuously monitored at 214 nm
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Figure 4.3 Mass chromatograms of EP67 and EP67 analogs. Cha =
cyclohexylalanine. Masses were measured on an Orbitrap Fusion Lumos from
ThermoScientific (Waltham MA) and with ≤ 0.5 ppm error. EP67: HRMS-ESI (m/z):
[M + H]+ calculated for (C57H88N14O15S + H), 1241.6352; found 1241.6350.
[Cha7]EP67: HRMS-ESI (m/z): [M + H]+ calculated for (C61H96N14O15S + H),
1297.6978; found 1297.6984. [Leu8]EP67: HRMS-ESI (m/z): [M + H]+ calculated
for (C56H86N14O15S + H), 1227.6196; found 1227.6196. [Cha 7Leu8]EP67: HRMSESI (m/z): [M + H]+ calculated for (C60H94N14O15S + H), 1283.6822; found
1283.6821.
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Figure 4.4 Experimental design for determining immunostimulant activity in
human mononuclear phagocytes and neutrophils. Monocytes (MC) and
neutrophils (NP) were isolated from the whole blood of healthy, human adult male
donors (19 to 59 y.o.) using Miltenyi magnetic anti-CD14 MicroBeads and
MACSxpress® Whole Blood Neutrophil Isolation Kits, respectively. Isolated NP
were plated for 2 h before treatment, whereas isolated CD14 +/CD14+CD16+ MC
were plated for 2 h before immunostimulant treatment or treated after
differentiation into M0-monocyte-derived macrophages (M0-MDM) (human GMCSF 6 d) or immature monocyte-derived dendritic cells (MDDC) (human GMCSF/Il-4 for 7 d). For potency studies, cells were incubated with increasing
concentrations of the indicated immunostimulant for 24 h and concentrations of IL6 and TNF-α [MC, M0-MDM, MDDC] or myeloperoxidase (MPO) [NP] released
into cell culture media was determined by ELISA. For kinetic studies, MC, M0MDM, and MDDC were incubated with the EC50 of the indicated immunostimulant
in the respective cell type and concentrations IL-6 and TNF-α released into cell
culture media were determined after 6, 12, 24, and 48 h by ELISA.
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Figure 4.5 Dose response of IL-6 and TNF-α secretion from human
monocytes, M0-monocyte-derived macrophages, and immature monocytederived dendritic cells after treatment with human C5a desArg, EP54, EP67,
or EP67 analogs for 24 h. Human monocytes (MC), unpolarized M0-monocytederived macrophages (M0-MDM), and immature monocyte-derived dendritic cells
(MDDC) were prepared from the whole blood of healthy, young human adult male
donors (Fig. 4.4). Cells were then treated with increasing concentrations of human
C5a desArg pooled from the blood of multiple donors (closed black circles), 1stgeneration EP54 (closed black squares), 2nd-generation EP67 (closed black
triangles), [Cha7]EP67 (open red circles), [Leu8]EP67 (open green squares), or
[Cha7, Leu8]EP67 (open blue triangles). After 24 h, average concentrations (± SD)
(n=2 replicates from 3 blood donors) of IL-6 or TNF-α secreted into the cell culture
media of human monocytes (A & D), M0-MDM (B & E), or MDDC (C & F) were
determined by ELISA and fit with a four-parameter dose-response curve where
Y=Min + (xHillslope)*(Max-Min)/(xHillSlope + EC50HillSlope)
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Figure 4.6 Dose response of IL-1β secretion from human monocytes,
uncommitted M0-monocyte-derived macrophages, and immature monocytederived dendritic cells after treatment with human C5a desArg for 24 h.
Human monocytes (MC), M0-monocyte-derived macrophages (M0-MDM), and
immature monocyte-derived dendritic cells (MDDC) were prepared from the whole
blood of healthy, young human adult male donors .Cells were then treated with
increasing concentrations of human C5a desArg pooled from the blood of multiple
donors. After 24 h, average concentrations (± SD) (n=2 replicates from 3 donors)
of IL-1β in the cell culture media of human monocytes (black circles), M0-MDM
(black squares), or MDDC (black triangles) were determined by ELISA and fit with
a four-parameter dose-response curve where Y=Min + (xHillslope)*(MaxMin)/(xHillSlope + EC50HillSlope). IL-1β release was not observed from MC, M0-MDM,
or MDDC after treatment with up to 1 mM of EP54, EP67, or EP67 analogs (not
shown). Values calculated from dose response curves. n = number of healthy,
young human adult male blood donors. aEC50 = average molar peptide
concentration that stimulated 50% maximum secretion of indicated cytokine
[±95%CI]. bEMAX = average maximum mass concentration of secreted cytokine
[±95%CI]. cpD2 = - log (EC50) [±95% CI].
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Figure 4.7 Comparison of potencies and efficacies for IL-6 and TNF-α
secretion from human mononuclear phagocytes after treatment with human
C5a desArg, EP54, EP67, or EP67 analogs for 24 h. Average (A) potencies
(EC50) and (B) efficacies (EMAX) ±95% CI for IL-6 (left Y-axis) and TNF-α (right Yaxis) were calculated from dose response curves of IL-6 and TNF-α secretion from
human monocytes (MC), M0-monocyte-derived macrophages (M0-MDM), and
monocyte-derived dendritic cells (MDDC) after treatment for 24 h. 0.05 level of
statistical difference vs. aEP67 (black triangles) for the indicated cytokine in the
same cell type.
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Figure 4.8 Dose response of myeloperoxidase release from human
neutrophils after treatment with human C5a desArg, EP54, EP67, or EP67
analogs for 24 h. (A) Human neutrophils (NP) were prepared from the whole blood
of healthy, young human adult male donors (18 to X y.o.) (Figure 4.4). NP were
then treated with increasing concentrations of human C5a desArg pooled from the
blood of multiple donors (black circles), 1st-generation EP54 (black squares), 2ndgeneration EP67 (black triangles), [Cha7]EP67 (open red circles), [Leu8]EP67
(open green squares), or [Cha7, Leu8]EP67 (open blue triangles). After 24 h,
average concentrations (± SD) (n=2 replicates from 3 blood donors) of
myeloperoxidase (MPO) released into cell culture media were determined by
ELISA and fit with a four-parameter dose-response curve where Y=Min +
(xHillslope)*(Max-Min)/(xHillSlope + EC50HillSlope). Average (B) potencies (Log EC50) and
(C) efficacies (EMAX) ±95% CI for MPO secretion were calculated from the MPO
dose response curves (A). a0.05 level of statistical difference vs. EP67.
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Figure 4.9. Comparison of selective activation of human mononuclear
phagocytes vs. human neutrophils after treatment with human C5a desArg,
EP54, EP67, or EP67 analogs for 24 h. Average selectivities ± propagated 95%
CI for stimulating the secretion of IL-6 or TNF-α from human (A) MC, (B) M0-MDM,
or (C) MDDC over secretion of MPO from human neutrophils (NP) were calculated
from respective EC50 values after treatment for 24
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Figure 4.10 Comparison of IL-6 and TNF-α cytokine release rates from human
monocytes, M0-monocyte-derived macrophages, and immature monocytederived dendritic cells after treatment with C5a desArg, EP54, EP67, or EP67
analogs. Human monocytes (MC), M0-monocyte-derived macrophages (M0MDM), and immature monocyte-derived dendritic cells (MDDC) were prepared
from the whole blood of healthy, young human adult male donors. Cell types were
then treated with the calculated EC50 of human C5a desArg pooled from the blood
of multiple donors (black closed circles), 1st-generation EP54 (black closed
squares), 2nd-generation EP67 (black closed triangles), [Cha 7]EP67 (red open
circles), [Leu8]EP67 (green open squares), or [Cha 7, Leu8]EP67 (blue open
triangles). At the indicated time points, average concentrations (± SD) (n=2
replicates from 3 donors) of IL-6 or TNF-α released into cell culture media by
human monocytes (A & D), M0-MDM (B & E), and MDDC (C & F) were determined
by ELISA.
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Peptide

C5a
C5a
desArg
EP54
EP67
[Cha7]EP67
[Leu8]EP67
[Cha7,
Leu8]EP67

Molecular
Amino Acid Sequence
mass
(g/mol)
--10,400
(±1,000) Ile65Ser66His67Lys68Asp69Met70Gln71Leu72Gly73Arg74
10,250
---Ile65Ser66His67Lys68Asp69Met70Gln71Leu72Gly73
(±1,000)
Tyr01Ser02Phe03Lys04Pro05Met06Pro07Leu08(d1209.6
Ala)09Arg10
Tyr01Ser02Phe03Lys04Asp05Met06Pro07(nme1241.6
Leu)08(D-Ala)09Arg10
Tyr01Ser02Phe03Lys04Asp05Met06Cha07(nme1297.7
Leu)08(D-Ala)09Arg10
Tyr01Ser02Phe03Lys04Asp05Met06Pro07Leu08(D1227.6
Ala)09Arg10
Tyr01Ser02Phe03Lys04Asp05Met06Cha07Leu08(D1283.7
Ala)09Arg10

Table 4.1. Relevant sequences and molecular masses of C5a, C5a desArg,
EP54, EP67, and EP67 analogs. Cha = cyclohexylalanine; nme-Leu = N-methyl
leucine. Molecular masses of C5a and C5a desArg vary due to differences in
glycosylation levels. C5a was not used in the current study because it is quickly
converted to C5a desArg in vivo.
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a

Peptide

EP54
EP67
[Cha7]EP67
[Leu8]EP67
[Cha7Leu8]EP67

c
ACE-5-PhenylACE-5-CN-300
300
Retention Purity Retention Purity Retention Purity
time
(%)
time
(%)
time
(%)
(min)
(min)
(min)

ACE-5-C18-300

24.4
27.4
34.4
26.1
34.5

86.2
96.9
96.4
99.1
97.4

b

24.9
27.4
33.1
25.1
31.8

87.2
96.1
93.9
99.0
95.5

23.8
22.3
28.9
20.7
28.2

87.2
94.4
96.5
99.7
99.2

Table 4.2. RP-HPLC Characteristics of EP54, EP67, and EP67 analogs. Cha
= cyclohexylalanine. Retention time and purity were determined from RP-HPLC
chromatograms using the indicated column. aACE 5 C18-300 column (250 x 4.6
mm). bACE 5 Phenyl-300 column (250 x 4.6 mm). cACE 5 CN-300 column (250 x
4.6 mm).
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Peptide

EP54
EP67
[Cha7] EP67
[Leu8] EP67
[Cha7Leu8] EP67

Calculated Mass
([M+H]+)

Experimental Mass
([M+H]+)

Error
(ppm)

1209.6454
1241.6352
1297.6978
1227.6196
1283.6822

1209.6455
1241.6350
1297.6984
1227.6196
1283.6821

0.1
0.2
0.5
0.0
0.2

Table 4.3. Measured molecular masses of EP54, EP67, and EP67 analogs.
Cha = cyclohexylalanine; nme-Leu = N-methyl leucine. Experimental masses
determined from mass chromatograms.
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Peptide
EP54

Asx

Ser

Ala

Met

Leu

Tyr

Phe

Lys

Arg

Pro

0.95 0.96 0.98 1.01 1.02 1.01 1.00 1.02 2.06
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
EP67
1.02 1.15 0.95 0.91
0.96 0.96 0.93 1.05 1.07
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
7
[Cha ]EP67
1.01 0.99 0.95 1.01
1.01 1.02 1.00 1.01
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
8
[Leu ]EP67
0.99 0.98 0.95 1.03 1.01 0.99 1.01 1.00 1.01 1.03
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
7
8
[Cha Leu ]EP67 1.00 0.99 0.96 1.02 1.02 1.00 1.02 1.00 1.01
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
Table 4.4. Amino acid compositions of EP54, EP67, and EP67 analogs. Cha
= cyclohexylalanine; nme-Leu = N-methyl leucine. Samples were subjected to
vapor-phase hydrolysis in constant boiling 6M hydrochloric acid for 24 hours prior
to being loaded on to a Hitachi 8800 Amino Acid Analyzer.

Peptide n
A. MC
C5a
desArg

3

EP54

3

EP67

3

7

[Cha ]EP6
7
[Leu8]EP6
7
[Cha7Leu8]
EP67

3
3
3

B. M0MDM
C5a
desArg

3

EP54

3

EP67

3

7

[Cha ]EP6
7
[Leu8]EP6
7
[Cha7Leu8]
EP67

3
3
3

C.
MDDC
C5a
desArg

3

EP54

3

EP67

3

7

[Cha ]EP6
7
[Leu8]EP6
7
[Cha7Leu8]
EP67

3
3
3

a

EC50 (nM)

b

EMAX (pg/mL)

pD2

e
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%C5a
desArg
Potency

IL-6

TNFα

IL-6

TNFα

0

0

100

100

1.9

1.3

1.4

4.4

1.7

1.2

2.2

6.8

1.61

1.09

2.48

8.16

1.69

1.20

2.06

6.28

7 [±0.1]

1.5

1.1

2.9

7.7

IL-6

TNF-α

IL-6

TNFα

IL-6

TNFα

527 [18,+21]
401 [16,+17]a
496 [14,+15]
426 [7,+8]a
403 [13,+14]a
411 [7,+7]a

8.6
[±0.1]
6.5
[±0.1]
6.78
[±0.09]
6.93
[±0.04]
6.81
[±0.08]
6.94
[±0.06]

8.3
[±0.1]
6.6
[±0.1]
6.8
[±0.1]
6.9
[±0.6]
6.9
[±0.1]
6.91
[±0.05]

0

0

100

100

2.1

1.7

0.89

1.9

1.81

1.5

1.56

3.2

1.65

1.4

2.21

4.0

1.77

1.5

1.70

3.5

1.64

1.42

2.28

3.78

IL-6

TNF-α

IL-6

TNF-α

IL-6

TNFα

IL-6

TNFα

4377 [289,+349]a
2331 [130,+136]a
3217 [65,+67]
3057 [79,+83]a
4525 [95,+98]a
2770 [50,+51]a

354 [17,+21]a
252 [7,+8]a
295 [14,+15]
253 [5,+5]a
427 [10,+10]a
268 [7,+6]a

8.7
[±0.2]
6.6
[±0.2]
6.7
[±0.06]
6.8
[±0.08]
6.8
[±0.07]
6.8
[±0.06]

8.2
[±0.2]
6.55
[±0.09]
6.6
[±0.1]
6.76
[±0.05]
6.72
[±0.07]
6.81
[±0.06]

0

0

100

100

2.1

1.64

0.8

2.28

1.9

1.6

1.12

2.5

1.90

1.43

1.26

3.70

1.90

1.47

1.25

3.40

1.86

1.38

1.387

4.13

IL-6

TNF-α

IL-6

TNF-α

IL-6

TNF-α

3 [0.7,+1]a
230 [54,+68]
147 [34,+43]
129 [10,+10]
155 [19,+22]
111 [16,+18]

8 [-3,+6]a
186 [26,+31]a
121 [-24,
+30]
101 [10,+11]
131 [24,+29]
108 [26,+34]

5386 [178,+197]a
3629 [133,+138]a
4622 [152,+159]
4462 [51,+51]
4229 [82,+84]a
4536 [105,+106]

428 [28,+38]a
295 [7,+7]a
388 [11,+11]
425 [6,+6]a
394 [11,+11]
376 [15,+16]b

8.4
[±0.1]
6.6
[±0.1]
6.8
[±0.1]
6.89
[±0.03]
6.81
[±0.06]
6.96
[±0.7]

8.1
[±0.2]
6.73
[±0.7]
6.9
[±0.1]
6.99
[±0.05]
6.88
[±0.09]

IL-6

TNF-α

IL-6

TNF-α

2.6 [0.5,+0.7]a
317 [86,+112]a
167 [31,+37]
118 [10,+11]a
153 [25,+29]
114 [14,+16]a

5 [-1,+1]a
239 [66,+86]
145 [29,+36]
116 [14,+15]
135 [30,+37]
123 [14,+15]

5231 [154,+161]a
3493 [142,+149]a
4683 [123,+128]
4277 [56,+56]a
4654 [109,+112]
3864 [73,+73]a

IL-6

TNF-α

2 [0.9,+2]a
254 [81,+112]
184 [24,+27]
164 [27,+32]
165 [25,+28]
149 [18,+21]

6 [-2,+3]a
281 [51,+61]
255 [74,+101]
173 [20,+23]
191 [29,+34]
155 [20,+22]a

∆C5a
desArg
d

c

Table 4.5 Potencies and EMAX of IL-6 and TNF-α secretion from human monocytes, M0monocyte-derived macrophages, and monocyte-derived dendritic cells after treatment
with human C5a desArg, EP54, EP67, or EP67 analogs for 24 h. Values were calculated from
dose response curves for (A.) human monocytes (MC), (B.) M0-monocyte-derived macrophages
(M0-MDM), and (C.) monocyte-derived dendritic cells (MDDC) (Figure 2). Cha =
cyclohexylalanine. n = number of healthy, young human adult male blood donors. aEC50 =
average molar peptide concentration that stimulated 50% maximum secretion of the indicated
cytokine [±95%CI]. bEMAX = average maximum mass concentration of secreted cytokine
[±95%CI]. cpD2 = - log (EC50) [±95% CI]. d∆C5a desArg = pD2 (C5a desArg) - pD2 (peptide).
e
%C5a desArg Potency = antilog (-∆C5a desArg) x 100.
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a

Peptide

n

NP

b

EC50
(µM)

EMAX
(ng/mL)

MPO

MPO

C5a desArg

3

*0.007
[±0.001]

*9.3 [±0.3]

EP54

3

*21 [-3, +4]

*5.6 [±0.2]

EP67

3

[Cha7]EP67
[Leu8]EP67
[Cha7Leu8]E
P67

3

160 [17,+20]
177 [21,+24]]
173 [19,+21]
190 [46,+61]

3.5 [±0.1]
*2.8 [±0.1]
3.4 [±0.1]
*2.6 [±0.2]

e

pD2

∆C5a
desArg

%C5a
desArg
Potency

MPO

MPO

MPO

0

100

3.46

0.0343

4.34

0.00453

4.39

0.00409

4.38

0.00419

4.4

0.0038

c

8.14
[±0.08]
4.67
[±0.08]
3.79
[±0.05]
3.75
[±0.05]
3.76
[±0.05]
3.7 [±0.1]

d

Table 4.6 Potencies and EMAX of myeloperoxidase secretion from human
neutrophils after treatment with human C5a desArg, EP54, EP67, or EP67
analogs for 24 h. Values were calculated from dose response curves of human
neutrophils (NP). Cha = cyclohexylalanine. n = number of healthy, young human
adult male blood donors. aEC50 = average molar concentration that stimulated 50%
maximum secretion of myeloperoxidase (MPO) [±95%CI]. bEMAX = average
maximum mass concentration of secreted MPO [±95%CI]. cpD2 = - log (EC50)
[±95% CI]. d∆C5a desArg = pD2 (C5a desArg) - pD2 (peptide). e%C5a desArg
Potency = antilog (-∆C5a desArg) x 100. *0.05 level of statistical difference vs.
EP67.
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a

MC vs. NP
Selectivity
IL-6
TNF-α

b

M0-MDM vs. NP
Selectivity
IL-6
TNF-α

c

MDDC vs. NP
Selectivity
IL-6
TNF-α

Peptide

n

C5a desArg

3

1

1

1

1

1

1

EP54

3

126 [±70]

3

[Cha7]EP67

3

[Leu8]EP67

3

23 [±10]
355
[±148]
525
[±189]
389
[±153]
603
[±225]

59 [±25]
708
[±295]
1047
[±392]
955
[±398]
1122
[±411]

29 [±17]

EP67

37 [±15]
447
[±175]
603
[±195]
490
[±169]
794
[±324]

52 [±21]
447
[±186]
708
[±259]
617
[±236]
891
[±334]

7

8

[Cha Leu ]EP
67

3

1413 [±789]
1905 [±995]
1145 [±795]
2188
[±1223]

302 [±113]
372 [±146]
363 [±139]
457 [±171]

Table 4.7 Selectivities of human C5a desArg, EP54, EP67, and EP67 analogs
for the activation of human monocytes, M0-monocyte-derived macrophages,
and monocyte-derived dendritic cells vs. human neutrophils. Average
selectivities [± propagated 95% CI] were calculated. Cha = cyclohexylalanine. n =
number of healthy, young human adult male blood donors. aMC vs. NP Selectivity
= [antilog (-∆C5a desArg MC) - (-∆C5a desArg NP)], bM0-MDM vs. NP selectivity
= [antilog (-∆C5a desArg M0-MDM) - (-∆C5a desArg NP)], and c MDDC vs. NP
selectivity = [antilog (-∆C5a desArg MDDC) - (-∆C5a desArg NP)] where ∆C5a
desArg = pD2 (C5a desArg) - pD2 (peptide) and pD2 = - log (EC50[M]) in the
respective cell types.
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CHAPTER 5

CONCLUSION AND FUTURE DIRECTIONS
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5.1 CONCLUSION
The decapeptide EP67 is a novel host-derived immunostimulants based on
the C-terminal of C5a that selectively activates phagocytes over neutrophils. In
contrast to C5a65-74 from the C5a parent molecule, EP67 has topographical
features that are well accommodated by C5aRs expressed on phagocytesmonocytes, macrophages, and dendritic cells, but not C5aRs neutrophils. Thus,
EP67 induces host innate immune responses against normal and resistant
infections via engagement of C5aR-bearing phagocytes with little/no inflammatory
side-effects associated with the direct activation of neutrophils.

The Pro residue at position 7 (Pro7) is critical for the potency and selectivity
of EP67. It was placed in this position to force an extended conformation at the
carbonyl carbon between the  and  bonds in the Met backbone to its Nterminus, a feature that was found to be biologically important from SAR studies
with the previous analog of EP67, EP54. The Pro residue, however, undergoes
cis/trans isomerization that leads to conformers of EP67 in solution, making it
unclear whether cis/trans isomerization is important to the biological properties of
EP67 or if one conformer is more effective than the other. What is clear is that the
conformational influence of Pro at this position is important for the activity and bioselectivity of EP67. Thus, the goals of this project were to (i.) develop a clinically
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relevant, high-throughput assay for screening immunostimulant activity in primary
human mononuclear phagocytes (monocytes, unpolarized (M0)-monocyte-derived
macrophages, monocyte-derived dendritic cells) and neutrophils and (ii.)
determine whether replacing Pro7 with cyclohexylalanine and/or nme-Leu8 with
leucine adversely affects EP67 potency and efficacy in human mononuclear
phagocytes and selective activation vs. human neutrophils.
In this project, we established a more clinically relevant, high throughput
assay to determine immunostimulants activity in human monocytes, unpolarized
monocytes-derived macrophages, monocytes-derived dendritic cells, and human
neutrophils. Using this assay, we found that replacing Pro7 with cyclohexylalanine
and/or nme-Leu8 with native Leu selectively affects EP67 potency and efficacy in
human mononuclear phagocytes without affecting selective activation over human
neutrophils. Thus, replacing Pro7 and nme-Leu8 with amino acids expected to
induce similar structure changes is a suitable approach for generating future
analogs of EP67.
5.2 FUTURE DIRCTIONS
Using our assay, we will continue screening for more EP67 analogs, and
we expect that at least one analog with a 5 to 10-fold higher C5aR potency and
bio-selectivity than EP67. Once identified, these analogs will be assessed for their
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effectiveness in inducing innate immune responses against resistant bacterial
(MRSA) infections. Briefly, we will demonstrate the therapeutic efficacy of
EP67/analog in inducing host-innate immune responses against local and
systemic methicillin-resistant Staphylococcus aureus (MRSA) infections in the
human-relevant porcine model. We will also evaluate both the prophylactic and
therapeutic efficacy of EP67/analog against these MRSA infections and will
characterize the molecular and cellular elements of innate immune outcomes
responsible MRSA reduction/elimination. We will establish the duration of the
EP67-mediated protective effects to MRSA infections in the skin, blood, and kidney
in our porcine model.
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